

Ibandronate (Boniva IV)

APPROVED FOR: OFFICE ADMINISTRATION

Indications for Prior Authorization

- Osteoporosis

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee.

- Padgett's disease
- Prevention of Osteoporosis

ALL OF THE FOLLOWING MUST BE MET:

- 1) Treatment of osteoporosis in postmenopausal woman
- 2) T-score is more than -2.5 SD below the young normal **or** the presence or history of osteoporotic fracture
and
- 3) Intolerable side effects with 2 of the following oral bisphosphonates: Fosamax or Actonel and Boniva.
or
- 4) Boniva injection should be reserved for patients with intrinsic swallowing mechanism defect who cannot take any oral formulary of medication.

Dosing

For Osteoporosis Treatment

The recommended dose is 3 mg every 3 months administered over a period of 15 to 30 seconds.